The purpose of this study was to investigate the cellular distribution of carnitine and its acyl derivatives in the normal and ischemic myocardium, and the effects of exogenous l-carnitine on this distribution and mitochondrial function in the ischemic dog heart. Under nonischemic conditions, about 93% of the total cellular carnitine was located in the cytosolic compartment and 6.5% in the mitochondrial compartment. Sixty minutes of ischemia induced a decrease in the cytosolic free carnitine content, but caused the accumulation of long-chain acylcarnitine in the cytosolic and mitochondrial compartments.
YOCARDIAL
carnitine deficiency has been demonstrated in many human and animal models of various types of heart disease, including heart failure1) and ischemic heart disease.2),3) A beneficial effect on the ischemic myocardium of treatment with l-carnitine has also been reported.4),5)
One of the possible mechanisms for a protective effect of l-carnitine in ischemia is the reduced myocardial accumulation of long-chain acyl CoA and long-chain acylcarnitine.6) However, Liedtke et al7) and Ichihara and Neely8) have demonstrated that administration of l-carnitine increased long-chain acylcarnitine formation when ischemic hearts were supplied with fatty acids despite its protection of myocardial function. Thus, the exact mechanism of the protective effect of l-carnitine on ischemic myocardium remains controversial.
Many key reactions related to free fatty acid (FFA) metabolism are thought to occur in a single cellular compartment, either the mitochondrial or the cytosolic compartment.
Acyl CoA and acylcarnitine are located in both the mitochondrial and cytosolic compartments. 9) Therefore, when investigating the protective effect of l-carnitine on the ischemic heart, it seems necessary to determine the changes in FFA metabolism in the individual subcellular compartments.
The purpose of this study was to assess the effect of l-carnitine treatment on the cellular distribution of carnitine and its acyl derivatives in the ischemic heart.
METHODS

Animals
Thirty-three male beagle dogs weighing 10-15kg were anesthetized with sodium pentobarbital (30mg/kg, i.v.), followed by infusion of the same agent at 5mg/kg/h during the experiment.
The left anterior descending coronary artery (LAD) was isolated immediately distal to the first diagonal branch. After a stabilization period, the LAD was occluded for 60min to produce acute myocardial ischemia.
The dogs were divided into 4 groups: a sham-operated normal group (n=8), an untreated group (n=8), and 2 l-carnitine-treated groups (n=16). The l-carnitine groups were a low dose group (30mg/kg, n=8) and a high dose group (100mg/kg, n=8).
In the l-carnitine groups, l-carnitine (30 or 100mg/kg) was administered as a bolus injection 5min before LAD occlusion. The untreated group received an equivalent volume of 7.26% NaCl solution as a control.
After occlusion of the LAD for 60min, the hearts were excised as rapidly as possible. Tissue samples were immediately freeze-clamped with a Wollenberger clamp pre-cooled in liquid nitrogen.
2. Isolation of the cytosolic and mitochondrial fractions Myocardial tissue was added to a four-fold volume of ice-cold isolation buffer (pH 7.4). The tissue suspension was homogenized twice for 10sec with a Polytron tissue homogenizer (PT-10, Kinematica), and the homogenate was divided into two fractions (A and B in Fig.1 -palmitoyl carnitine were completely recovered in the mitochondrial post-supernatant fraction and mitochondrial residual fraction, respectively, whereas neither form of labeled carnitine was detected in mitochondrial fractions I and II (Table I ). This indicated that carnitine was not transferred from the cytosolic to the mitochondrial compartment during preparation of the speciments.
1. Changes in carnitine and its derivatives during preparation Table II shows the changes in the content of various carnitine metabolites during preparation. The levels of free carnitine and its derivatives were not different between the frozen tissue and the homogenates. Similarly, there was no difference in the levels of these carnitine metabolites between cytosol I and 
